• Dabrafenib plus trametinib shows promise over docetaxel for BRAF-mutated NSCLC

    4 days ago - By Healio

    CHICAGO - Combination therapy with dabrafenib and trametinib conferred longer survival than docetaxel for patients with BRAF V600E-positive non-small cell lung cancer, according to results of an adjusted indirect comparison presented at the International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.“In the absence of head-to-head trials, indirect comparisons of the efficacy of novel targeted therapy vs. standard of care can provide valuable evidence to inform clinical and economic decision-making,” Medha Sasane, from Novartis Oncology, said...
    Read more ...